271 related articles for article (PubMed ID: 28440004)
1. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
Kavakli K; Demartis F; Karimi M; Eshghi P; Neme D; Chambost H; Sommer L; Zak M; Benson G
Haemophilia; 2017 Jul; 23(4):575-582. PubMed ID: 28440004
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
3. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
[TBL] [Abstract][Full Text] [Related]
5. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
Valentino LA; Cooper DL; Goldstein B
Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
[TBL] [Abstract][Full Text] [Related]
6. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
Nicolaisen EM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S119-23. PubMed ID: 9819042
[TBL] [Abstract][Full Text] [Related]
7. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
8. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
9. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
10. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
[TBL] [Abstract][Full Text] [Related]
11. Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia.
Hay CRM; Sharpe T; Dolan G;
Haemophilia; 2017 May; 23(3):376-382. PubMed ID: 28026073
[TBL] [Abstract][Full Text] [Related]
12. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
[TBL] [Abstract][Full Text] [Related]
13. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
Nakar C; Cooper DL; DiMichele D
Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
[TBL] [Abstract][Full Text] [Related]
14. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
[TBL] [Abstract][Full Text] [Related]
15. NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.
Rice KM; Savidge GF
Haemostasis; 1996; 26 Suppl 1():131-4. PubMed ID: 8904187
[TBL] [Abstract][Full Text] [Related]
16. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
Morfini M; Bjerre J
Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry.
Chambost H; Santagostino E; Laffan M; Kavakli K;
Haemophilia; 2013 Jul; 19(4):571-7. PubMed ID: 23557542
[TBL] [Abstract][Full Text] [Related]
19. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
Tiede A; Worster A
Ann Hematol; 2018 Oct; 97(10):1889-1901. PubMed ID: 29804265
[TBL] [Abstract][Full Text] [Related]
20. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
Abshire T; Kenet G
Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
